Novartis Rejiggers Pharma To Favor Oncology
Executive Summary
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.
You may also be interested in...
Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.
Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches
Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.
Novartis Drug Discovery Centralization Brings R&D Relocations, Job Cuts
Novartis' efforts to rationalize and centralize its drug discovery programs will see the Novartis Institute for Tropical Diseases moved from Singapore to California and the closure of biologics units in Shanghai and in the Swiss town of Schlieren.